In this Healthed lecture, Professor Henry Brodaty explains the evidence for the effectiveness of Donanemab in slowing cognitive and functional decline, with the greatest benefit being seen in early-stage patients. In addition, he will discuss the practical aspects of the treatment including patient selection, assessment, referral process as well as how the monthly IV infusions are delivered, monitored, and potential side effects. Professor Brodaty will also address the reality that the effectiveness of donanemab is not universal and careful patient selection and managing expectations is important.

<p>In this Healthed lecture, Professor Henry Brodaty explains the evidence for the effectiveness of Donanemab in slowing cognitive and functional decline, with the greatest benefit being seen in early-stage patients. In addition, he will discuss the practical aspects of the treatment including patient selection, assessment, referral process as well as how the monthly IV infusions are delivered, monitored, and potential side effects. Professor Brodaty will also address the reality that the effectiveness of donanemab is not universal and careful patient selection and managing expectations is important.</p>

Healthed's medical education channel features the latest high quality clinical interviews and lectures from leading experts in their field, offering health professionals a convenient new way to boost their knowledge.

Healthed Australia

Donanemab – A GP guide to anti-amyloid therapies

https://api.omny.fm/orgs/8365a4b5-1eb4-4780-971d-aad20051c830/clips/369bcbb9-70b7-406c-ba86-b2f900299478/transcript

Advertisement